SBMP-microcarrier SBMP - disrupting the manufacturing of biological drugs through a ground-breaking nanotechnology-based microcarrier
- Coordinator
- Cellevate AB, Sweden
- Runs
- 1 October 2022 to 30 September 2024
- Status
- Finished
- EU funding
- €2.5m
- Total cost
- €3.6m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190187799
What the project is doing
In the project's own words, from its summary on CORDIS.
Cellevate proposes a completely novel type of nanofibrous microcarriers for adherent cell culture in bioreactors based on the proprietary Superior Biologics Manufacturing Platform (SBMP). It is a game-changing deep-tech innovation for the biopharmaceutical industry. SBPM-microcarriers are highly customizable, faithfully replicate the 3D extracellular environment found in the human body, and provide a 60 times larger area for cell growth compared to competitive solutions.
The unique scaffold properties are a result of a patent-pending nanofiber scaffold production technology (PCT/EP2020/081958) which creates networks of polymer nanofibers that can be handled in a liquid form, unachievable by competing solutions. By offering high yields and ensuring the optimal conditions for human cell growth, SBMP-microcarriers have the potential to transform the biopharmaceutical market by pushing the limits of today’s biological drugs production to an unachievable level of quality and efficiency.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Cellevate AB | Lund | Sweden | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI